Table 2.
IgE antibodies targeting cancer antigens.
| IgE species | IgE specificity | Nomenclature | Technology used for production | Expression system | In vitro results | Route of IgE in vivo administration | Targeted cancer cells (route of cell inoculation) | Mouse model | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Passive immunotherapy studies: | |||||||||
| Mouse | gp36 of MMTV | Clone A8 and H11 | Murine hybridoma | Fusion of spleen cells with P3X20 myeloma cells | NR | i.p. | H2712 mouse mammary carcinoma (s.c. and i.p.) | C3H/HeJ | (Nagy et al., 1991) |
| Rat/human chimeric | Mouse Ly-2 | YTS169.4 | Genetic engineering | Murine hybridoma YTS169.4L | ADCC mediated by murine T cells expressing chimeric FcεRI | s.c. | E3 mouse thymoma (s.c.) | C57BL/6 | (Kershaw et al., 1996) |
| Mouse and mouse/human chimeric | Colorectal cancer antigen | mIgE 30.6 and chIgE 30.6 | Genetic engineering | Murine myeloma (Sp2/0) | Antigen binding affinity | i.v. | Human COLO 205 (s.c.) | SCID | (Kershaw et al., 1998) |
| Rat/human chimeric | Mouse Ly-2 | YTS169.4 | Genetic engineering | Murine hybridoma YTS169.4L | ADCC mediated by human T cells expressing chimeric FcRεI | i.p. | E3 mouse thymoma (i.p.) | NOD-SCID | (Teng et al., 2006) |
| Mouse/human chimeric | FBP | MOv18IgE | Genetic engineering | Murine myeloma (Sp2/0-Ag14) | Degranulation and ADCC cytotoxicity mediated by platelets | i.v. | IGROV1 human ovarian carcinoma cells (s.c.) | C.B-17 scid/scid | (Gould et al., 1999) |
| ADCC and ADCP mediated by human monocytes, ADCC mediated by human eosinophils | i.p. | HUA patient-derived ovarian carcinoma (i.p.) | nu/nu | (Karagiannis et al., 2003; 2007; 2008) | |||||
| Humanized | HER2/neu | Trastuzumab IgE | Genetic engineering | HEK293 | Antigen binding affinity, degranulation, ADCC, interaction with human monocytes, and direct cytotoxicity in human breast cancer cells | NR | NR | NR | (Karagiannis et al, 2009) |
| Human | HER2/neu | C6MH3-B1 IgE | Genetic engineering | Murine myeloma (P3X63Ag8.653) | Degranulation and IgE-facilitated antigen stimulation | i.p. | D2F2/E2 mouse mammary carcinoma cells expressing human HER2/neu (i.p.)2 | Human FcεRIα Tg BALB/c | (Daniels et al., 2012) |
| Mouse/human chimeric | EGFR | 425 IgE and 225IgE | Genetic engineering | HEK293 | Direct cytotoxity induced by 425 IgE, ADCC mediated by 225 IgE and human monocytes | NR | NR | NR | (Spillner et al., 2012) |
| Mouse/human chimeric | MUC1 | 3C6.hIgE | Genetic engineering | CHO-K1 | NR | s.c. | 4T1 tumour cells expressing human MUC1 (s.c.) | Human FcεRIα Tg BALB/c | (Teo et al., 2012) |
| Mouse/human chimeric | CD20 | 1F5.hIgE | Genetic engineering | CHO-K1 | ADCC using human mast cells and eosinophils as effector cells | NR | NR | NR | (Teo et al., 2012) |
| Vaccination studies: | |||||||||
| Mouse | DNP | mAb SP6 | Murine hybridoma (purchased from Sigma Chemical Co.) | Murine hybridoma | NT | i.p. | MC38 mouse colon carcinoma cells expressing human CEA (s.c.) 1 | C57BL/6 | (Reali et al., 2001) |
| Mouse | DNP | SPE7 | Murine hybridoma (purchased from Sigma Aldrich) | Murine hybridoma | Degranulation of haptenized cells | s.c. | TS/A-LACK mouse mammary carcinoma cells coated with DNP (s.c.) | BALB/c | (Nigro et al., 2009) |
| Mouse/human chimeric | NIP | Anti-NIP IgE | Genetic engineering | J558L murine myeoma | Degranulation of haptenized cells | s.c. | TS/A-LACK mouse mammary carcinoma cells coated with NIP (s.c.) | Human FcεRIα Tg BALB/c | (Nigro et al., 2009) |
| Human (truncated) | N/A | tmIgE | Genetic engineering | Chicken embryo fibroblasts | Degranulation | s.c. | TS/A-LACK mouse mammary carcinoma cells coated with truncated IgE (s.c.) | Human FcεRIα Tg BALB/c | (Nigro et al., 2012) |
| Mouse/human chimeric | PSA | Anti-PSA IgE | Genetic engineering | Murine myeloma (Sp2/0-Ag14) | Degranulation and IgE-facilitated antigen stimulation | s.c. | CT26 tumour cells expressing human PSA (s.c.) | Human FcεRIα Tg BALB/c | (Daniels-Wells et al., 2013) |
1
Tumour targeting occurred via a biotinylated anti-CEA IgG followed by streptavidin and then a biotinylated IgE
2
A pilot toxicity study also conducted in non-human primates (cymolgus monkeys)
DNP: dinitrophenol (hapten), EGFR: epidermal growth factor receptor, FBP: folate binding protein, HEK: human embryonic kidney, HER2/neu: human EGFR2/neuroblastoma, i.p.: intraperitoneal, i.v.: intravenous, MMTV: mouse mammary tumour virus, MUC1: mucin-1, cell surface associated, NIP: nitrophenylacetyl (hapten), NR: not reported, PSA: prostate-specific antigen, s.c.: subcutaneous, Tg: transgenic